Table 1 of
Sangwan, Mol Vis 2022; 28:526-535.
Table 1. Details of the chronic ocular sequelae in SJS/TEN patients (n=98 eyes).
| Ocular complications Severity grade (0–5) | Severity Grade, N(%) | |||||
|---|---|---|---|---|---|---|
| Absent (0) | Mild (1) | Moderate (2) | Severe (3) | Very severe (4) | Severe most (5) | |
| Loss of palisades of Vogt (POV) | 12(12.2) | 16(16.3) | 16(16.3) | 28(28.6) | 20(20.4) | 6(6.2) |
| Conjunctivalization (CONC) | 12(12.2) | 15(15.3) | 17(17.4) | 28(28.6) | 19(19.4) | 7(7.1) |
| Vascularization (VASC) | 11(11.2) | 18(18.4) | 30(30.6) | 25(25.5) | 10(10.2) | 4(4.1) |
| Keratinization (KERT) | 59(60.2) | 12(12.2) | 7(7.1) | 5(5.1) | 11(11.2) | 4(4.2) |
| Superficial punctate keratopathy (SPK) | 77(78.6) | 12(12.2) | 6(6.1) | 3(3.1) | - | - |
| Opacification (OPAC) | 10(10.2) | 15(15.3) | 24(24.5) | 27(27.6) | 17(17.4) | 5(5.1) |
| Meibomian gland involvement (MGI) | 12(12.2) | 40(40.8) | 28(28.6) | 18(18.4) | - | - |
| MucocutaneousJunction involvement (MCI) | 9(9.2) | 22(22.5) | 36(36.7) | 19(19.4) | 9(9.2) | 3(3.1) |
| Punctal involvement (PUNC) | 38(38.8) | - | 60(61.2) | - | - | - |
| Hyperaemia (HYPER) | 23(23.5) | 35(35.7) | 29(29.6) | 8(8.2) | 1(1.0) | 2(2.0) |
| Conjunctival keratinization (CKERT) | 61(62.2) | 7(7.1) | 10(10.2) | 10(10.2) | 7(7.2) | 3(3.1) |
| Symblepharon formation (SYMB) | 46(46.9) | 30(30.6) | 9(9.2) | 5(5.1) | 6(6.1) | 2(2.1) |